Market Overview

Evotec and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto

Share:
  • LAB150 is a joint effort by MaRS Innovation and Evotec
  • Selection and acceleration of early-stage drug discovery projects
    originating from leading academic institutions and teaching hospitals
    in Toronto (Canada)

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
and MaRS Innovation ("MI") today announced the launch of "LAB150". This
transformational Toronto-based partnership will give Canadian academic
institutions and teaching hospitals access to the world-class
infrastructure and drug discovery expertise of Evotec and pair it with
cutting-edge drug discovery projects emerging from the 15 member
institutions of MaRS Innovation.

A crucial lack of the funding, specialised infrastructure and drug
development expertise necessary to translate disease-related biological
pathways into focused drug discovery programmes has been a persistent
hindrance for promising biomedical research to reach clinical
development and the marketplace in Canada and globally. LAB150 addresses
precisely this challenge. The goal of this new partnership is to
significantly shorten the drug discovery timeline and to generate viable
start-up companies with high potential for success.

MI will identify projects and build technical and business cases from
scientific concepts that focus on first-in-class and disease-related
novel biological pathways. Evotec will contribute infrastructure and
pre-clinical drug development expertise to translate such discoveries
into potential medicines.

Dr Rafi Hofstein, President & CEO of MI, said: "LAB150 represents an
extraordinary opportunity for Canada to bridge the drug discovery gap
with the objective of stimulating the formation of new ventures in
downtown Toronto and of developing ground-breaking therapies to benefit
Canadians and others around the world." Dr Werner Lanthaler, Chief
Executive Officer of Evotec, commented: "We are delighted to expand our
Academic BRIDGE network and partnerships together with MaRS Innovation.
The dramatic reduction of search costs for capital for the first
translational work packages of academic science, early validation of
experiments, and industry-proven drug discovery processes will add a
highly valuable new tool to the Canadian ecosystem of innovation."

Evotec is seeking partnerships across all biotechnology innovation hubs
and has selected MI and Toronto as a top-notch venue for its first North
American partnership. This is a testament not only to MI's novel
approach to commercialisation but also to the quality of science and
innovation of MI's member institutions. Supported by financial
contributions from both MI and Evotec, this newly formed five-year
partnership will accelerate the development and commercialisation of
Canadian-born therapies delivered globally. MI and Evotec are already
collaborating on other projects, notably Fibrocor Therapeutics LP, a
company based in Toronto, which focuses on developing first-in-class
therapeutics targeting fibrotic diseases.

The name of this partnership, LAB150, commemorates Canada's 150th
anniversary.

About MaRS

Innovation MaRS Innovation is the commercialization agent for 15 of
Ontario's leading academic institutions including the University of
Toronto and its affiliated research hospitals, York University, and
Ryerson University. Supported by the Government of Canada through the
Networks of Centres of Excellence, by the Government of Ontario through
the Ontario Centres of Excellence, and by its members, MaRS Innovation
is a transformational partnership that turns research strengths into
commercial opportunities through industry partnerships, licensing and
company creation. MaRS Innovation represents over $1.47 billion of R&D
funding annually, a portfolio of 60 companies, $160M in outside risk
capital, and is credited with creating over 400 jobs. For more
information please visit www.marsinnovation.com.

About Evotec AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with
leading pharmaceutical and biotechnology companies, academics, patient
advocacy groups and venture capitalists. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic to meet the industry's
need for innovation and efficiency in drug discovery (EVT Execute). The
Company has established a unique position by assembling top-class
scientific experts and integrating state-of-the-art technologies as well
as substantial experience and expertise in key therapeutic areas
including neuroscience, diabetes and complications of diabetes, pain and
inflammation, oncology and infectious diseases. On this basis, Evotec
has built a broad and deep pipeline of more than 80 partnered product
opportunities at clinical, pre-clinical and discovery stages (EVT
Innovate). Evotec has established multiple long-term discovery alliances
with partners including Bayer, CHDI, Sanofi or UCB and development
partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with Sanofi in the field of diabetes and with
Pfizer in the field of tissue fibrosis. For additional information
please go to www.evotec.com.

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates
or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on
which any such statement is based.

Language:   English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial
Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart,
Tradegate Exchange

View Comments and Join the Discussion!